Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will present at the 2021 Wedbush PacGrow Healthcare Conference on August 10, 2021, at 2:55 p.m. ET. A live webcast of the presentation will be available on Kiniksa's website, with a replay accessible for 14 days post-conference. The company focuses on developing therapeutic medicines for patients with significant unmet medical needs, including its portfolio of assets such as ARCALYST®, mavrilimumab, vixarelimab, and KPL-404, targeting various debilitating diseases.

News Market Reaction – KNSA

-15.65%

-15.65% Session move

In the trading session that priced this news, KNSA declined 15.65%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAMILTON, Bermuda, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 2:55 p.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of assets, ARCALYST^® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts!™ Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com

FAQ

When will Kiniksa Pharmaceuticals present at the Wedbush PacGrow Healthcare Conference?

Kiniksa Pharmaceuticals will present at the Wedbush PacGrow Healthcare Conference on August 10, 2021, at 2:55 p.m. ET.

Where can I watch the Kiniksa Pharmaceuticals conference presentation?

You can watch the Kiniksa Pharmaceuticals conference presentation live on their website under the Investors & Media section.

How long will the Kiniksa Pharmaceuticals conference presentation replay be available?

The replay of Kiniksa Pharmaceuticals' conference presentation will be available for 14 days following the conference.

What are the main therapeutic assets of Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' main therapeutic assets include ARCALYST®, mavrilimumab, vixarelimab, and KPL-404, targeting conditions with significant unmet medical needs.